AOD-9604

AOD-9604 is the last sixteen amino acids of human growth hormone — residues 176 to 191 — synthesised on their own. The idea behind it is one of the more elegant in peptide research: growth hormone does several different things, and if the parts of the molecule responsible for each could be separated, one activity might be studied without the others.

Work in the 1980s and 1990s suggested that the tail end of the hormone carried its effects on fat metabolism while the growth-promoting activity depended on other regions. A fragment of that tail should therefore influence fat handling without acting on growth or on blood glucose — the properties that make full growth hormone difficult to work with. AOD-9604 was developed at Monash University on precisely that reasoning.

It is also the compound in this catalogue with the most instructive negative result. Unlike most research peptides, it was taken into randomised placebo-controlled human trials, and the outcome was clear: no significant difference from placebo. That is a more valuable thing to know about a compound than most of what is written about the others here.

• Separating a hormone's functions: Whether the distinct activities of a large hormone can be split apart into separate fragments is a general question in peptide design. This compound is one of the most thoroughly pursued attempts to answer it.

• Fat cell metabolism in vitro: The original findings came from isolated fat cells, where the fragment altered measures of fat breakdown and synthesis. Those cell-level observations remain the most solid part of its record.

• A receptor-independent route: It does not appear to act through the growth hormone receptor, which is unusual for a fragment of that hormone and is itself a reason researchers continue to examine how it works.

• A documented clinical failure: Its Phase II trial found no difference from placebo. Studying why a mechanism that holds in cell culture and in mice does not translate to people is a legitimate and under-served research question.

Growth hormone is a chain of 191 amino acids folded into a specific shape, and different regions of that shape do different jobs. The region that binds the growth hormone receptor drives growth and the production of IGF-1. Separate work indicated that effects on fat tissue could be traced to the far end of the molecule, and that this end might act without engaging the receptor at all.

Fat cells continually store and release fat, and the balance between the two determines how much they hold. Studies of this fragment in isolated fat cells reported shifts in that balance — more breakdown of stored triglyceride, less synthesis of new fat. Because the effect appeared without receptor engagement, the mechanism was proposed to run through a different route, possibly involving the receptors that respond to adrenaline.

The gap between that account and the clinical result is the useful part. Isolated fat cells in a dish have no hormonal context, no blood supply and no regulatory feedback; a person has all three. A mechanism that operates in a dish and in a mouse but produces nothing measurable in a randomised trial is a reminder of how much those missing layers can absorb.

The clinical evidence is unusually complete and unusually negative. AOD-9604 went through Phase II development for obesity and did not separate from placebo on the primary endpoint, after which development for that indication stopped. Safety was not the problem; efficacy was.

The cell-culture and rodent work that preceded the trial is published, and the compound has since been examined in other contexts including cartilage research. It holds no medicines approval and is supplied for laboratory research only. What makes it a useful research subject is precisely the mismatch between its preclinical and clinical records, which is a question few compounds let you study directly.

AICAR and 5-Amino-1MQ are the other single-target compounds in this category, both acting on defined enzymes rather than on receptors, and both still at the preclinical stage this compound has already passed through.

L-Carnitine provides the contrast between a signalling approach and a supply one — one attempts to change the instruction, the other provides the machinery. Adipotide is further away still: it was designed to remove tissue rather than to alter how it behaves.